Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries and the third-leading cause in developing countries. Dry AMD, unlike the neovascular, wet form, has no effective therapies available today – bad news, especially as it comprises about 85–90 percent of all AMD cases. Then again, a number of potentially disease-modifying therapies are currently under clinical evaluation, so this situation may change in the future.
In 2015, we benchmarked the PubMed-listed AMD literature as a whole (1), and we’ve also reviewed the entirety of the AMD trial data that’s available on clinicaltrials.gov (2). This month, we set out to specifically assess the dry AMD literature. To provide insight into the past and predictions for the future of the field, a series of metrics were applied to the last five years of published literature.
We asked:
- Who has published the most?
- Who has had the greatest impact?
- What are the big topics being discussed?
- Is this knowledge available online (for free or for a fee)?
References
- M Hillen, “Benchmarking AMD”, The Ophthalmologist, 17, 38–40 (2015). Available at: http://top.txp.to/issues/0315/501/. Accessed January 23, 2017. M Hillen, R McGuigan, “AMD Clinical Trials”, The Ophthalmologist, 22, 38–40 (2015). Available at: http://top.txp.to/issues/0815/501/. Accessed January 23, 2017.
